Contact
searchSearch
HMP Global

Get Permissions

For permissions, please visit our pages on the Copyright Clearance Center Marketplace.

Popular Now

FDA
News
FDA Preliminary Evaluation Finds No Clear Link Between GLP-1 Drugs and Suicidal Thoughts, Cautions on Small Risk
01/26/2024
Meagan Thistle
The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation...
01/26/2024
Psych Congress Network
lab work
News
Dosing Starts in Pharmacokinetics Study of AD04 for Alcohol Use Disorder
07/08/2024
Jolynn Tumolo
A pharmacokinetics study of AD04, a potential treatment for AUD, is designed to meet an FDA requirement for an upcoming phase 3 trial and is expected to last 6 months.
A pharmacokinetics study of AD04, a potential treatment for AUD, is designed to meet an FDA requirement for an upcoming phase 3 trial and is expected to last 6 months.
A pharmacokinetics study of...
07/08/2024
Psych Congress Network
Client at Pharmacy
News
Financial, Insurance Barriers May Interfere with Buprenorphine Dispensing at Pharmacy
04/02/2024
Jolynn Tumolo
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance...
04/02/2024
Psychiatry & Behavioral Health
marc agronin md
Faculty Insights
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
fda
News
FDA Approves Iloperidone for Acute Treatment of Bipolar I Disorder
04/08/2024
Meagan Thistle
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for...
04/08/2024
Psych Congress Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use